AMRN Amarin Corporation plc

15.86
+0.41  (+3%)
Previous Close 15.45
Open 15.44
Price To Book 44.06
Market Cap 5,665,421,621
Shares 357,214,478
Volume 4,797,939
Short Ratio
Av. Daily Volume 6,879,110
Stock charts supplied by TradingView

NewsSee all news

  1. Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

    Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

  2. Amarin to Participate in the Cantor Global Healthcare Conference

    DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve

  3. National Lipid Association's New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins

    Millions of Patients on Statins with Elevated Triglycerides Are at Risk of Cardiovascular Events, Such as Heart Attack, Stroke or Death Icosapent Ethyl Recognized as Only Non-LDL-Cholesterol Lipid Management Treatment

  4. New 2019 Updates to the European Society of Cardiology's and European Atherosclerosis Society's Guidelines for the Management of Dyslipidaemias Incorporate Findings from the REDUCE-IT™ Cardiovascular Outcomes Study

    BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that the European

  5. Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference

    BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Advisory Committee meeting November 14, 2019. PDUFA date under priority review September 28, 2019 extended to December 28, 2019.
Vascepa
High Triglycerides With Mixed Dyslipidemia

Latest News

  1. Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

    Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

  2. Amarin to Participate in the Cantor Global Healthcare Conference

    DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve

  3. National Lipid Association's New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins

    Millions of Patients on Statins with Elevated Triglycerides Are at Risk of Cardiovascular Events, Such as Heart Attack, Stroke or Death Icosapent Ethyl Recognized as Only Non-LDL-Cholesterol Lipid Management Treatment

  4. New 2019 Updates to the European Society of Cardiology's and European Atherosclerosis Society's Guidelines for the Management of Dyslipidaemias Incorporate Findings from the REDUCE-IT™ Cardiovascular Outcomes Study

    BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that the European

  5. Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference

    BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve

  6. Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Cholesterol Management

    Multiple Papers and Presentations Highlight REDUCE-IT and Vascepa®Potential Mechanisms of Action of Vascepa Becoming Better Understood American Heart Association References REDUCE-IT in Scientific Advisory BEDMINSTER,